Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165129 | 1.00 | USP2 (0.51) | USP2LMNAMAPTTSHRMAPK1 | |
| SCHEMBL31049792 | 0.86 | HSD17B10 (0.49) | MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL27145826 | 0.86 | HSD17B10 (0.49) | MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL29165086 | 0.86 | HSD17B10 (0.49) | MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL30019310 | 0.82 | HRH2 (0.45) | MAPTL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL30019151 | 0.79 | HRH2 (0.42) | MAPT | |
| SCHEMBL23868438 | 0.78 | L3MBTL3 (0.64) | USP2LMNAMAPTTSHRMAPK1 | |
| SCHEMBL27348451 | 0.78 | KHK (0.52) | USP2LMNAMAPTTSHRMAPK1 | |
| SCHEMBL28495248 | 0.78 | HTT (0.49) | LMNA | |
| SCHEMBL18693576 | 0.78 | HTT (0.49) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4326724-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2024-02-28 | — | — | EP | disclosed |
| CN-117120443-A | Compounds as adenosine A2a receptor antagonists and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | USP2 3619/4885LMNA 3812/4885MAPT 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.